Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.

Yunwei WangJennifer WangJoel PekowSushila DalalRussell D CohenJacob OllechAmanda IsraelBenjamin D ShoganDejan MicicLisa CannonKonstantin UmanskiyRoger HurstNeil HymanDavid T RubinAtsushi Sakuraba

Published in: Journal of gastroenterology and hepatology (2019)

Vedolizumab was effective and safe in maintaining remission in IBD patients who switched from anti-TNF agents due to reasons other than failure of therapy. Our results suggest that switching anti-TNF remitters to VDZ treatment is a safe practice in specific patient populations.

Keyphrases

ulcerative colitis
rheumatoid arthritis
newly diagnosed
healthcare
primary care
patients undergoing
stem cells
prognostic factors
case report
patient reported outcomes
bone marrow
genetic diversity